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Disruption of Epstein-Barr virus latency is induced by expression of either the BZLF1 (in B cells and
epithelial cells) or BRLF1 (in epithelial cells only) immediate-early protein. Regulation of BZLF1 and BRLF1
transcription may therefore modulate the stringency of viral latency. The cellular transcription factor YY1
negatively regulates BZLF1 transcription. Here we show that the BRLF1 promoter (Rp) sequences from 2206
to 2227 (relative to the mRNA start site) and from 27 to 16 are directly bound by YY1. Mutation of the
upstream YY1 binding site increases constitutive Rp activity in epithelial cells and B cells, while mutation of
the downstream YY1 binding site does not significantly affect Rp activity. Negative regulation of BZLF1 and
BRLF1 transcription by YY1 may act to maintain viral latency.
Epstein-Barr virus (EBV) is a human herpesvirus which is
associated with the development of B-cell lymphomas and na-
sopharyngeal carcinoma (30, 57). Infection in B cells results in
primarily latent infection, whereas infection of epithelial cells
is more frequently permissive (20, 25, 30, 46). Expression of
the EBV immediate-early (IE) gene product BZLF1 (Z) dis-
rupts viral latency in B cells (4, 5, 7, 18, 38, 39, 47). In epithelial
cells, expression of either BZLF1 or another EBV IE gene
product, BRLF1 (R), disrupts viral latency (15, 52). Therefore,
the transcriptional regulation of both the BZLF1 and BRLF1
gene products by cellular factors is critical in determining the
stringency of viral latency.
Disruption of viral latency may require not only the activa-
tion of cellular transcription factors which positively regulate
BZLF1 and/or BRLF1 transcription but also the inactivation
of repressor factors. The BZLF1 gene product is primarily
derived from the Zp promoter, and the BRLF1 gene product
is primarily derived from the Rp promoter (27). In addition,
small amounts of BZLF1 may be derived from Rp, since the
messages derived from this promoter have the potential to
translate the BZLF1 gene product bicistronically (27).
The BZLF1 promoter (Zp) has been extensively studied and
shown to contain a number of positive, as well as negative,
regulatory elements. Important positively regulating elements
in Zp include the ZII motif (a CREB-like motif which helps
mediate 12-O-tetradecanoylphorbol-13-acetate [TPA] induc-
tion) and the ZI motifs (which act as positive regulators in the
presence of TPA but negative regulators in the absence of
TPA) (10, 11, 40). Zp is bound by the cellular YY1 transcrip-
tion factor and is negatively regulated by this protein (33, 34).
A series of HI motifs (some of which overlap the YY1 binding
sites) have also been shown to negatively regulate BZLF1
transcription (41).
Chemical and biological agents which disrupt EBV latency
activate Zp and Rp transcription essentially simultaneously (9,
21, 35, 48), suggesting that BZLF1 and BRLF1 expression is
regulated through common cellular transcription factors. The
BRLF1 promoter contains Sp1 binding sites, which are impor-
tant for constitutive activity (53), and Zif268 (Egr-1) binding
sites, which are required for TPA-induced stimulation (54).
However, specific cellular factors which regulate both Zp and
Rp transcription have not been identified (19).
In this study, we show that Rp, like Zp, contains binding sites
for YY1 and is negatively regulated by this cellular transcrip-
tion factor. The YY1 (yin-yang 1) protein is a Kruppel-related
zinc finger protein which functions as either a negative or
positive regulator, depending upon the position in the pro-
moter and the cellular environment (8, 16, 36, 44). Our results
suggest that YY1 promotes EBV latency by negatively regu-
lating the two viral IE proteins which induce lytic infection.
Binding of cellular proteins to Rp was assessed in electro-
mobility shift assays (EMSAs) (12). A 32P-labelled DNA probe
spanning the Rp sequences from 2188 to 16 was incubated
with a nuclear cell extract derived from Raji cells (a latently
infected EBV-positive Burkitt’s lymphoma cell line). Binding
reaction mixtures consisted of 20,000 cpm of the 32P-end-la-
belled probe incubated with 4 mg of nuclear extract in a buffer
consisting of 50 mM Tris (pH 7.9), 250 mM NaCl, 2.5 mM
EDTA, 5 mM dithiothreitol, 5 mM MgCl2, and 50% glycerol.
Poly(dI-dC) z poly(dI-dC) (4 mg) was added as a nonspecific
competitor DNA, and the final volume was adjusted to 20 ml.
As shown in Fig. 1, the BRLF1 promoter is bound by several
different proteins in Raji cell extracts. One of these complexes
is the previously reported Sp1 complex (53). Another complex,
previously designated complex B (53), was specifically com-
peted by the murine leukemia virus YY1 binding site (8) but
not by a series of other competitor DNAs. Thus, complex B,
which we have previously shown is present in both B cells and
epithelial cells (53), may in fact be the YY1 transcription
factor.
To confirm that YY1 binds to Rp, partially purified bacterial
YY1 fusion protein (produced from a construct containing the
YY1 cDNA cloned into the pDS56-6X His vector) (a gift from
Tom Shenk) was incubated with 20,000 cpm of radioactively
labelled BRLF1 probe (containing Rp sequences from2188 to
16) in a buffer consisting of 20 mM HEPES (pH 7.9), 5 mM
MgCl2, 0.5 mM EGTA, 50 mM KCl, 0.25 mM ZnSO4, 10 ng of
bovine serum albumin per ml, and 7% glycerol. The reaction
mixture was loaded on a 4% polyacrylamide–Tris-glycine gel
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and run in 13 Tris-glycine buffer (0.025 mM Tris, 0.19 M
glycine) at 20 mA at room temperature. The bacterial extracts
containing the vector alone (pDS56-6X His) did not bind to
Rp, whereas the YY1-expressing bacterial extracts produced a
complex binding to Rp which was specifically competed by the
murine leukemia virus YY1 binding site but not competed by
competitor DNA containing the Ap1 motif (Fig. 2). A probe
containing the BRLF1 sequences from 2179 to 2575 pro-
duced similar results (data not shown). Thus, there appear to
be at least two YY1 binding sites in the BRLF1 promoter.
To determine the exact sites of YY1 binding in the BRLF1
promoter, we performed methylation protection studies as pre-
viously described (53). The 32P-end-labelled BRLF1 probes
(100,000 cpm) were incubated with 2 volumes of the reaction
mix used in the EMSAs (containing partially purified bacterial
YY1 protein) and treated with dimethylsulfate immediately
before loading the reaction mixture on the gel. The YY1-
competed bands and free probes were cut separately from the
gel, transferred to DEAE membrane paper, incubated with 1
M piperidine at 908C for 15 min, and then eluted with high-salt
buffer. Equal amounts of radioactive bound and free probes
were then loaded on a 6% polyacrylamide–7 M urea gel and
subjected to autoradiography.
As shown in Fig. 3A and B, two YY1 binding sites in Rp
were defined in these experiments. The first (downstream)
YY1 site is located over the BRLF1 mRNA initiation start site.
The second (upstream) YY1 binding site is located between
2206 and 2227 (relative to the BRLF1 mRNA start site). To
confirm that the sites defined in Fig. 3A and B bind YY1,
labelled oligonucleotide probes spanning each of the two YY1
binding sites were incubated with bacterially synthesized YY1
in an EMSA (Fig. 3C). The two Rp oligonucleotide probes
bound YY1 with similar efficiency, whereas a control oligonu-
cleotide probe (spanning the CCAAT motif in the early EBV
BHLF1 promoter) did not bind YY1. Likewise, unlabelled
oligonucleotides spanning either of the two BRLF1 YY1 sites
efficiently competed against YY1 binding (from HeLa cell nu-
clear extracts) to a labelled probe containing the murine leu-
kemia virus YY1 site (8), whereas oligonucleotides containing
specific mutations in the BRLF1 YY1 sites did not compete
(Fig. 3D). Finally, a labelled BRLF1 probe (containing the
BRLF1 promoter sequences from2254 to 16) in which the two
YY1 sites were both specifically mutated no longer bound the
YY1-competed complex in HeLa cell nuclear extracts (Fig. 3E).
The functional significance of the YY1 sites in Rp was ex-
amined in transient reporter gene assays. Site-directed mutants
altering each of the YY1 sites in the RpBSCAT construct
(which contains the Rp sequences from 2962 to 15 linked to
the chloramphenical acetyltransferase [CAT] gene) (54) were
made with the Bio-Rad in vitro mutagenesis kit as shown in
Fig. 4a. The wild-type and mutant RpBSCAT plasmids were
transfected into HeLa epithelial cells or EBV-positive Raji
Burkitt cells as previously described (54), and the level of CAT
activity induced by each construct was measured (14).
As shown in Fig. 4b and c, mutation of the upstream YY1
site alone in Rp increased the constitutive activity of the RpB-
SCAT plasmid in both HeLa and Raji cells. Thus, the up-
stream YY1 binding site may function as a negative regulator
of Rp. In contrast, mutation of the downstream YY1 site
alone, which is positioned over the mRNA start site, slightly
reduced Rp activity in HeLa cells and had little effect in Raji
cells. Simultaneous mutation of both YY1 sites reduced Rp
activity in HeLa cells but increased Rp activity in Raji cells.
Disruption of EBV latency can be induced by a variety of
agents, including the phorbol ester TPA, and anti-immuno-
FIG. 1. A YY1-like factor binds to Rp. A 32P-labelled probe containing Rp
sequences (from 2188 to 16) was incubated with Raji cell nuclear extract in an
EMSA. Raji cell extracts contain a complex binding to the Rp probe which is
specifically competed with unlabelled oligonucleotide competitor DNA contain-
ing the YY1 binding site from the murine leukemia virus LTR (YY1) but is not
competed by cold competitor DNA containing the Ap1 or Sp1 binding motif.
The potential YY1 complex, the previously identified Sp1 complex (53), and the
as yet unidentified A complex are indicated in brackets.
FIG. 2. Bacterially synthesized YY1 binds to Rp. Protein extracts from
HB101 bacteria expressing the YY1 protein linked to a His tag (a gift from Tom
Shenk) versus extracts from HB101 bacteria containing the pDS56-6X His vector
were incubated with radioactively labelled BRLF1 probe (containing Rp se-
quences from 2188 to 16). A labelled BRLF1 probe containing Rp sequences
from 2179 to 2575 also bound bacterially synthesized YY1 (data not shown).
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FIG. 3. Mapping of YY1 sites in Rp. 32P-labelled probes containing Rp sequences from2188 to16 (A) or2179 to2575 (B) were incubated with partially purified
bacterial YY1 protein, and a methylation protection assay was performed. The bands representing the YY1-bound (lanes B) and free probe (lanes F) are shown. Areas
of partial YY1-induced protection are indicated. The BRLF1 promoter sequence is shown in the regions of protection, numbered relative to the BRLF1 mRNA
initiation site. (C) Labelled oligonucleotides containing the Rp promoter sequences indicated (spanning each of the YY1-protected regions shown in panels A and B)
were incubated with extracts from HB101 bacteria expressing the YY1 protein or extracts from HB101 bacteria containing the pDS56-6X His vector. Each of the Rp
probes bound to the bacterially synthesized YY1 protein, whereas the control probe (containing the CCAAT motif from the EBV BHLF1 promoter) did not. (D) A
labelled oligonucleotide probe containing the YY1 binding motif from the murine leukemia virus LTR (8) was incubated with HeLa cell nuclear extract and competed
with cold oligonucleotides containing either the Sp1 binding motif, the NF-kB binding motif, sequences spanning the upstream BRLF1 promoter YY1 binding site (lane
YY1-2), sequences spanning the downstream BRLF1 YY1 binding site (lane YY1-1), or oligonucleotides which had been mutated within the upstream (lane DYY1-2)
and downstream (lane DYY1-1) YY1 binding sites as shown in Fig. 4a. (E) A 32P-labelled probe containing the wild-type BRLF1 promoter sequences from 2254 to
16 or a mutant BRLF1 probe spanning the same sequences but mutated over the two YY1 sites (as shown in Fig. 4a) was incubated with HeLa cell nuclear extract
and competed with cold oligonucleotide competitor DNA containing either the Sp1 binding motif or the YY1 binding motif (from the murine leukemia virus LTR)
(8).
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globulin cross-linking of surface immunoglobulin (21, 48).
Agents which disrupt EBV latency could mediate their effects
by modulating YY1 binding to the BRLF1 and/or BZLF1
promoters. Montalvo et al. have reported that TPA treatment
of Raji cells is associated with loss of YY1 binding to the
BZLF1 promoter (although the intracellular level of YY1 is
not affected), whereas cross-linking of surface immunoglobulin
does not affect YY1 binding to Zp (34). We examined the
effect of TPA and cross-linking of surface immunoglobulin on
YY1 binding to the BRLF1 promoter (Fig. 5). Nuclear extracts
were prepared from uninduced Akata cells (48) or cells treated
for various times (from 0.5 to 4 h as indicated) with anti-human
immunoglobulin G (100 mg/ml) and used in EMSAs with la-
belled probes spanning the two Rp YY1 binding sites. The
level of YY1 binding to Rp was not altered by cross-linking of
surface immunoglobulin in Akata cells, even though BZLF1
binding to Rp was clearly induced. Induction of lytic viral
infection in the B95-8 cell line with TPA (20 ng/ml) likewise
had no effect on YY1 binding to either of the YY1 sites in Rp
(data not shown). Therefore, disruption of EBV latency by
cross-linking of surface immunoglobulin or TPA does not ap-
pear to require loss of YY1 binding to the BRLF1 promoter.
YY1 regulates the expression of numerous different viruses.
The adeno-associated virus P5 promoter (44), the human im-
munodeficiency virus type 1 long terminal repeat (LTR) (28),
the human cytomegalovirus major IE gene (26), and the LTR
of murine leukemia virus (8) are transcriptionally repressed by
YY1. In contrast, YY1 activates expression of the P6 promoter
of B19 parvovirus (32) and the major capsid protein (VP5)
gene of herpes simplex virus type 1 (3, 31). YY1 can either
positively or negatively regulate the long control region of
human papillomavirus, depending upon the cell type and the
presence or absence of a switch region (1, 2).
YY1 function is modulated by viral and cellular proteins.
The adenovirus E1A protein converts YY1 from a negative to
a positive regulator of AAV transcription, without affecting
DNA binding of YY1 (44). Relief of YY1-induced transcrip-
tional repression by E1A may involve direct interactions be-
tween E1A and YY1 (24), as well as interactions between the
E1A-associated protein, p300, and YY1 (23). In the case of the
c-fos promoter, YY1 represses transcription by physically in-
teracting with ATF/CREB proteins bound to the 267 cyclic
AMP response element, and E1A reverses this effect by dis-
rupting the ATF/CREB-YY1 complex (13, 55, 56). YY1 also
directly interacts with Sp1 and modulates Sp1-dependent tran-
scription (22, 43). c-Myc (45), cyclophilin A, and FK506-bind-
ing protein 12 (50) have likewise also been recently shown to
directly interact with and regulate YY1.
In this report, we have identified two YY1 binding sites in
the BRLF1 promoter. The downstream site (CGGCCTTTT) is
located over the BRLF1 transcription initiation site, and the
upstream site (GAGTGACATCTT) is located between 2206
and 2227 relative to the RNA start site. Both sites are similar
(but not identical) to the preferred YY1 binding motif ([C/g/a
][G/t][G/t/a]CATN[T/a][T/g/c], where capital letters indicate
the preferred sequence and lowercase letters indicate possible
substitutions) (17, 51). Under appropriate conditions, YY1 can
function as an initiator element, binding to the core promoter
and recruiting the polymerase to the initiation complex (42,
49). The downstream Rp YY1 site, located over the transcrip-
tional initiation site, could thus function as an initiator ele-
ment. In HeLa cells, mutation of the downstream YY1 site
alone had little effect on Rp activity, suggesting that YY1
binding at this site is not necessarily required for transcription
initiation. Nevertheless, in the context of the upstream YY1
binding site mutation (a mutation which increases constitutive
Rp activity), mutation of the downstream YY1 site significantly
reduced Rp activity in HeLa cells. Thus, it remains possible
that under certain conditions the downstream YY1 binding site
is required for efficient transcriptional initiation.
Deletion of the upstream YY1 site increased Rp activity in
both HeLa cells and Raji cells. Thus, the upstream YY1 site
FIG. 3—Continued.
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may function as a negative regulator of BRLF1 transcription.
We have previously shown that the constitutive activity of Rp
is considerably greater in epithelial cells than in B cells (53).
Deletion of the upstream YY1 binding site increased Rp ac-
tivity considerably more in HeLa cells than in Raji cells, sug-
gesting that additional factors repress Rp activity in Raji cells
even in the absence of YY1 binding. Although we have defined
the upstream BRLF1 YY1 site as a negatively regulating ele-
ment in this report, YY1 effects are notoriously cell type de-
pendent and influenced by a myriad of different factors (1, 2,
44, 45, 50). Thus, it would not be surprising if the upstream
YY1 site in Rp could function as a positive regulator under
certain conditions.
Montalvo et al. have likewise reported that YY1 binding
sites in the BZLF1 promoter function as cis-acting negative
elements (33, 34). Disruption of EBV latency could therefore
require inhibition of YY1 binding or modulation of YY1 func-
tion. We did not find that either TPA treatment of cells or
cross-linking of surface immunoglobulin reduced YY1 binding
to the BRLF1 promoter, although Montalvo et al. have re-
ported that TPA reduces YY1 binding to the BZLF1 promoter
(34). However, as is the case with the E1A protein, TPA
treatment of cells or cross-linking of surface immunoglobulin
could regulate YY1 function without affecting its DNA binding
capacity.
Suppression of BZLF1 and BRLF1 transcription is likely
required for the maintenance of viral latency in epithelial cells
(52). Lytic viral infection may be selected against during the
evolution of nasopharyngeal carcinoma, since this EBV-asso-
ciated epithelial malignancy involves predominently latent in-
fection (37). Cervical carcinomas induced by extrachromo-
FIG. 4. Functional significance of YY1 binding sites in Rp. (a) Site-directed mutations of the RpBSCAT vector were constructed as shown, altering each of the two
YY1 binding sites. (b) Five micrograms of the wild-type or mutant RpBSCAT plasmids was transfected into HeLa cells, and CAT assays were performed 2 days after
transfection as described previously (14, 53). Results are normalized such that the activity of wild-type RpBSCAT plasmid in each experiment is set at 100%. (c)
Experiments were performed as described for panel b, except in the EBV-positive Burkitt lymphoma line, Raji.
FIG. 5. Anti-immunoglobulin treatment of Akata cells does not affect YY1
binding to Rp. Nuclear extracts were prepared from uninduced Akata cells or
cells treated for various times (from 0.5 to 4 h as indicated) with anti-human
immunoglobulin G (IgG) and used in EMSAs with labelled probes spanning the
two BRLF1 YY1 binding sites. The positions of the Sp1, BZLF1 (Z), YY1, and
A binding complexes are indicated in brackets. Similar results were obtained with
a probe spanning the upstream YY1 binding site in Rp (data not shown).
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somal human papillomavirus type 16 often contain mutations
which alter YY1 sites within the long control region (6, 29).
Modulation of YY1 regulation in EBV-associated tumors
could likewise affect the stringency of EBV latency.
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